01 September 2022: Clinical Research
High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy
Iwona Homa-Mlak 1ACDEF* , Radosław Mlak 1ACDEF , Anna Brzozowska 2BDF , Marcin Mazurek 1CEF , Tomasz Powrózek 1CDF , Monika Prendecka-Wróbel 1CEF , Aneta Szudy-Szczyrek 2ADE , Piotr Dreher 3CEF , Katarzyna Kamińska 4F , Teresa Małecka-Massalska 1ACEF , Alicja Wójcik-Załuska 5CEGDOI: 10.12659/MSM.936857
Med Sci Monit 2022; 28:e936857
Table 2 Influence of demographic and clinical factors on irisin level in HNC patients.
| Factor | Irisin level median (95% CI) | p | |
|---|---|---|---|
| Gender | Male | 1.36 (1.22–1.46) | 0.1006 |
| Female | 1.12 (0.74–1.50) | ||
| Age (years) | ≥65 | 1.41 (1.21–1.65) | 0.1378 |
| 1.27 (1.10–1.41) | |||
| Histopathological diagnosis | Carcinoma planoepitheliale | 1.34 (1.17–1.44) | 0.4969 |
| Other | 1.22 (−) | ||
| Tumor location | Upper and middle | 1.53 (1.05–1.71) | 0.7166 |
| Lower | 1.33 (1.17–1.41) | ||
| Lower and middle | 1.33 (1.17–1.42) | 0.4869 | |
| Upper | 1.55 (−) | ||
| T stage | T1–T2 | 1.27 (0.79–1.57) | 0.2970 |
| T3–T4 | 1.34 (1.18–1.45) | ||
| N stage | N0 | 1.38 (1.22–1.56) | 0.5191 |
| N1–N3 | 1.24 (1.14–1.44) | ||
| M stage | M0 | 1.35 (1.20–1.45) | 0.2282 |
| Mx and M1 | 1.17 (−) | ||
| Performance status (ECOG) | 1 | 1.33 (1.19–1.43) | 0.5198 |
| 2 | 1.47 (−) | ||
| Alcohol consumption | Yes | 1.43 (1.14–1.59) | 0.2120 |
| No | 1.23 (1.15–1.39) | ||
| Tobacco smoking | Yes | 1.38 (1.17–1.51) | 0.3543 |
| No | 1.24 (0.99–1.43) | ||
| Treatment | Surgery+RTH | 1.39 (1.19–1.46) | 0.5936 |
| Other | 1.23 (1.13–1.55) | ||
| Surgery+chemoradiation | 1.22 (1.07–1.53) | 0.5701 | |
| Other | 1.37 (1.18–1.49) | ||
| RTH alone | 1.13 (−) | 0.1796 | |
| Other | 1.34 (1.22–1.45) | ||
| Induction CTH+RTH | 1.55 (−) | 0.7906 | |
| Other | 1.33 (1.18–1.42) | ||
| Concurrent chemoradiation | 1.53 (−) | 0.2933 | |
| Other | 1.28 (1.17–1.43) | ||
| CTH – chemotherapy; ECOG – Eastern Cooperative Oncology Group; M – metastatic spread; N – lymph node involvement; RTH – radiotherapy; T – tumor site and size; TNM –Tumor, Node, Metastasis staging. | |||